AMED Preclinical tau PET study

Exploratory clinical study on usefulness of tau PET imaging on diagnosis and evaluation of preclinical- and prodromal-stage Alzheimer's disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051190065

Enrollment

Registered

2019-10-23

Start date

2019-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preclinical AD, Mild Cognitive Impairment (MCI) Dementia Alzheimer disease

Interventions

PET scan using an unapproved PET drug

D000072760

Positron emission tomography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subjects who are enrolled in the AMED Preclinical study 2.Informed consent to participate in this tau PET study 3.Able to undergo the tau PET scan within 2 years from the baseline visit of the AMED Preclinical study

Exclusion criteria

Exclusion criteria: 1.Subjects who should not undergo the tau PET scan as judged by the physician in charge. 2.Subjects who will not be able to complete the tau PET scan

Design outcomes

Primary

Measure	Time frame
Tau PET	—

Contacts

Public ContactHiroyuki Shimada

Osaka City University Graduate School of Medicine.

h.shimada@med.osaka-cu.ac.jp+81-6-6646-6185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026